CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression
{{output}}
Introduction: Prostate cancer is a leading cause of cancer-related mortality in men worldwide, and the treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a major clinical challenge. CD24, a glycosylated ... ...
